Interní Med. 2016; 18(1): 6-8 | DOI: 10.36290/int.2016.002

New options in the treatment of hypercholesterolaemia

prof. MUDr. Vladimír Soška, CSc.1,2,3, MUDr. Ondřej Kyselák1
1 Oddělení klinické biochemie, ICRC &ndash, oddělení kardiovaskulárních chorob, FN u sv. Anny v Brně
2 Katedra laboratorních metod, LF MU Brno
3 II. interní klinika, LF MU Brno

Statins are the key drugs for LDL-cholesterol lowering: they have a lot of evidences that they decrease not only cholesterol, but also cardiovascular events and mortality. Second-line choice for lowering LDL-cholesterol is ezetimibe, which is intended to combination with statins. This year were published results of IMPROVE-IT study which showed that addition of ezetimibe to statin has also clinical benefit – decrease of cardiovascular events. New lipid-lowering drugs are PCSK9-inhibitors, first two of which were already approved for clinical use.

Keywords: hypercholesterolemia, LDL-cholesterol, statins, ezetimibe, PCSK9-inhibitors

Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soška V, Kyselák O. New options in the treatment of hypercholesterolaemia. Interní Med. 2016;18(1):6-8. doi: 10.36290/int.2016.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670-1681. Go to original source... Go to PubMed...
    2. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670-1681. Go to original source... Go to PubMed...
    3. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011; 217(1): 3-46. Go to original source... Go to PubMed...
    4. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. The New England journal of medicine. 2015; 372(25): 2387-2397. Go to original source... Go to PubMed...
    5. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American heart journal. 2008; 156(5): 826-832. Go to original source... Go to PubMed...
    6. Leiter LA, Lundman P, da Silva PM, Drexel H, Junger C, Gitt AK, et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabetic medicine : a journal of the British Diabetic Association. 2011; 28(11): 1343-1351. Go to original source... Go to PubMed...
    7. Federici M. Effect of ezetimibe on cholesterol absorption and lipoprotein composition in diabetes and metabolic syndrome. Atherosclerosis Supplements. 2015; 17: 17-22. Go to original source... Go to PubMed...
    8. Ruggenenti P, Cattaneo D, Rota S, Iliev I, Parvanova A, Diadei O, et al. Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care. 2010; 33(9): 1954-1956. Go to original source... Go to PubMed...
    9. Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: A New Therapeutic Mechanism for Reducing Cardiovascular Disease Risk. Circulation. 2015; 132(17): 1648-1666. Go to original source... Go to PubMed...
    10. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014; 129(2): 234-243. Go to original source... Go to PubMed...
    11. Li C, Lin L, Zhang W, Zhou L, Wang H, Luo X, et al. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. Journal of the American Heart Association. 2015; 4(6): e001937. Go to original source... Go to PubMed...
    12. Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015; 36(19): 1186-1194. Go to original source... Go to PubMed...
    13. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014; 63(13): 1278-1288. Go to original source... Go to PubMed...
    14. Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015. Go to original source... Go to PubMed...
    15. Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015; 385(9965): 331-340. Go to original source... Go to PubMed...
    16. Ling H, Burns TL, Hilleman DE. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol. Cardiovascular therapeutics. 2014; 32(2): 82-88. Go to original source... Go to PubMed...
    17. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014; 63(23): 2541-2548. Go to original source... Go to PubMed...
    18. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. The New England journal of medicine. 2014; 370(19): 1809-1819. Go to original source... Go to PubMed...
    19. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014; 311(18): 1870-1882. Go to original source... Go to PubMed...
    20. Bays H, Gaudet D, Weiss R, Ruiz JL, Watts GF, Gouni-Berthold I, et al. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. The Journal of clinical endocrinology and metabolism. 2015; 100(8): 3140-3148. Go to original source... Go to PubMed...
    21. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. The New England journal of medicine. 2015; 372(16): 1500-1509. Go to original source... Go to PubMed...
    22. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. The New England journal of medicine. 2015; 372(16): 1489-1499. Go to original source... Go to PubMed...
    23. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Annals of internal medicine. 2015; 163(1): 40-51. Go to original source... Go to PubMed...
    24. Aronow WS. Treatment of Hypercholesterolemia in 2015. American journal of therapeutics. 2015.
    25. Markham A. Alirocumab: First Global Approval. Drugs. 2015; 75(14): 1699-705. Go to original source... Go to PubMed...
    26. Markham A. Evolocumab: First Global Approval. Drugs. 2015; 75(13): 1567-1573. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.